₹-0.63
(Market cap
₹10 Cr
Revenue (TTM)
₹19 Cr
P/E Ratio
772.8
P/B Ratio
1.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹0 Cr
-
ROE
6.3 %
-
ROCE
10.2 %
-
Industry P/E
44.98
-
EV/EBITDA
9
-
Debt to Equity
0.4
-
Book Value
₹18.3
-
EPS
₹0
-
Face value
10
-
Shares outstanding
5,071,700
10 Years Aggregate
CFO
₹9.29 Cr
EBITDA
₹11.03 Cr
Net Profit
₹3.61 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Beryl Drugs
| -15.3 | -19.8 | -8.5 | -0.9 | 12.3 | 13.1 | -6.0 |
|
BSE Healthcare
| 8.8 | 8.8 | 9.7 | 11.0 | 27.5 | 14.1 | 12.0 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Beryl Drugs
| -35.1 | 60.3 | 70.1 | 7.3 | 45.6 | 60.9 | -48.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Beryl Drugs
|
19.8 | 10.1 | 19.1 | 0.0 | 0.9 | 0.1 | 772.8 | 1.1 |
| 2,951.2 | 24,140.1 | 1,339.4 | 356.4 | 33.2 | 23.2 | 67.8 | 14.6 | |
| 418.6 | 16,010.4 | 2,268.6 | 150.1 | 10.6 | 5.4 | 89.3 | 4.1 | |
| 752.0 | 18,624.4 | 5,365.6 | 595.0 | 16.6 | 13.3 | 31.3 | 3.7 | |
| 1,006.4 | 16,019.7 | 8,279.6 | 397.8 | 9.9 | 6.4 | 40.2 | 2.3 | |
| 1,169.7 | 20,961.2 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 13.5 | 2.4 | |
| 1,834.5 | 21,027.8 | 1,421.6 | -73.8 | 1.8 | -1.1 | -- | 3.6 | |
| 175.6 | 23,328.3 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.9 | |
| 461.9 | 18,639.4 | 3,738.7 | 316.7 | 12.5 | 7.5 | 58.9 | 3.9 | |
| 1,575.4 | 25,598.2 | 3,373.0 | 199.0 | 12.6 | 5.9 | 120.2 | 5.2 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Beryl Drugs
Beryl Drugs Limited manufactures and markets branded and generic pharmaceutical formulations in India. The company offers I.V. fluids and small volume injectables, as well as veterinary products. It also provides research and development, and... contract manufacturing services. Beryl Drugs Limited was founded in 1993 and is based in Indore, India. Read more
-
Incorporated
1993
-
Chairman
Sudhir Sethi
-
Managing Director
Sanjay Sethi
-
Headquarters
Indore, Madhya Pradesh
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
FAQs for Beryl Drugs
What is the current share price of Beryl Drugs Ltd Today?
The share price of Beryl Drugs Ltd is ₹19.81 (BSE) as of 22-May-2026 IST. Beryl Drugs Ltd has given a return of 12.27% in the last 3 years.
What is the current PB & PE ratio of Beryl Drugs Ltd?
The P/E ratio of Beryl Drugs Ltd is 772.85 times as on 22-May-2026, a 1618 premium to its peers’ median range of 44.98 times.
The P/B ratio of Beryl Drugs Ltd is 1.08 times as on 22-May-2026, a 72 discount to its peers’ median range of 3.85 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.45
|
1.13
|
|
2024
|
19.35
|
1.67
|
|
2023
|
8.05
|
0.77
|
|
2022
|
0.00
|
0.73
|
|
2021
|
13.99
|
0.42
|
What is the 52 Week High and Low of Beryl Drugs Ltd?
The 52-week high and low of Beryl Drugs Ltd are Rs 30.00 and Rs 15.92 as of 24-May-2026.
What is the market cap of Beryl Drugs Ltd?
Beryl Drugs Ltd has a market capitalisation of ₹ 10 Cr as on 22-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Beryl Drugs Ltd?
Before investing in Beryl Drugs Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.